Cancer Research· 2017Q1
Discovery of IDO1 Inhibitors: From Bench to Bedside
- 569citations
- Q1SCImago
- 2017year
Short summary
Small-molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging as a new class of cancer therapeutics, with indoximod, epacadostat, and navoximod being the first evaluated in clinical trials.
AI-generated from the title and abstract; the full text is not read.
Key points
- IDO1 inhibitors represent a novel class of experimental cancer agents.
- Indoximod, epacadostat, and navoximod were the first IDO inhibitors to undergo clinical trials.
- IDO1 inhibitors function as immunometabolic adjuvants.
- These inhibitors may broaden the therapeutic window for various cancer treatments.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Small-molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide a bench-to-bedside review on preclinical validation of IDO1 as a cancer therapeutic target and on the discovery and development of a set of mechanistically distinct compounds, indoximod, epacadostat, and navoximod, that were first to be evaluated as IDO inhibitors in clinical trials. As immunometabolic adjuvants to widen therapeutic windows, IDO inhibitors may leverage not only immuno-oncology modalities but also chemotherapy and radiotherapy as standards of care in the oncology clinic. Cancer Res; 77(24); 6795–811. ©2017 AACR.
The authors' abstract, as published at the source. Cancer Research, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Biological Psychiatry
Biological PsychiatryNeuroscience